Cemex SAB de CV Down Over 7%, on Pace for Largest Percent Decrease Since February 2022 — Data Talk
Cemex SAB de CV Sponsored ADR (CX) is currently at $5.81, down $0.44 or 7.08%
--Would be lowest close since April 26, 2023, when it closed at $5.79
--On pace for largest percent decrease since Feb. 10, 2022, when it fell 8.06%
--Currently down four of the past five days
--Up 43.4% year-to-date; on pace for best year since 2016, when it rose 49.93%
--Down 79.14% from its all-time closing high of $27.84 on June 15, 2007
--Up 61.77% from 52 weeks ago (Oct. 6, 2022), when it closed at $3.59
--Down 30.62% from its 52-week closing high of $8.37 on Aug. 29, 2023
--Up 81.48% from its 52-week closing low of $3.20 on Oct. 14, 2022
--Traded as low as $5.79; lowest intraday level since April 26, 2023, when it hit $5.77
--Down 7.32% at today's intraday low; largest intraday percent decrease since Oct. 27, 2022, when it fell as much as 8.11%
All data as of 2:02:34 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 05, 2023 14:24 ET (18:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks